Given that the expression levels of miR-489 is strongly correlated with tumor aggressive phenotypes, it raises the possibility that targeting miR-489 as a therapy may be of benefit not just in HER2/neu-overexpressing tumors, but also in a broader subsets of patients. Here, ERBB2 is linked to neoplasm.